Skip to main content

Logo
  • Live News iconLive News
  • Smart Screener iconSmart Screener
  • Trade Opportunities iconTrade Opportunities
  • Alpha Watch iconAlpha Watch
  • Catalyst iconCatalyst
Skip to main content
Stock Ask Logo
Hi, Guest User

Log in or create an account to get full access

Open an Account (opens in a new window)

TOOLS

Live News
Smart Screener
Trade Opportunities
Alpha Watch
Catalyst

StockkASK powered by Indira Securities

Denis Chem Lab Ltd (DENISCHEM) Share Price & Fundamentals

Company Overview

Founded Year

1980

Listed Year

-

Headquarter

India

MD/CEO

Dr. Himanshu C. Patel

Website

http://www.denischemlab.com

Company Facts

What we do

Denis Chem Lab Ltd manufactures pharmaceutical transfusion solutions and intravenous fluids using advanced Blow Fill Seal technology, serving the healthcare sector with sterile injectable products.

Founded in

1,980

Market share

A leading manufacturer in India's IV fluids segment with growing market presence in premium Eurohead products.

Problem solved

Provides safe, sterile intravenous fluids and transfusion solutions crucial for medical treatments and patient hydration.

Top clients or who we serve

Hospitals, healthcare providers, and pharmaceutical companies; operates primarily B2B and third-party manufacturing for injectables.

Key management

Dr. Himanshu C. Patel (Managing Director) with leadership focus on expansion and modernization.

Our journey and innovations

Started in 1984, innovated with BFS technology for plastic IV fluids in 2007, expanded Eurohead Aquapulse range in 2018 and 2021.

Where we operate

Primarily India domestic market with expanding geographical reach through enhanced distribution.

Top products or what we offer

Sterile IV fluids in glass and plastic bottles (100-1000 ml), Aquapulse Eurohead IV fluids, third-party manufacturing services.

Top brands

Aquapulse - premium Eurohead IV fluid brand with 12 lakh bottles/month capacity; key revenue driver.

Raw materials needed

Pharmaceutical grade chemicals and plastics for IV fluid production.

Raw materials supplier

Suppliers of medical-grade bulk drugs and plastics; specific names not disclosed.

Recurring vs cyclical contribution

Revenue largely recurring through steady IV fluid and transfusion solution demand.

Our industry position

Strong position in Indian sterile IV fluid segment with growing premium product line and third-party manufacturing.

Financial highlights

FY 2024-25 Revenue: Rs 173.3 Cr, Net Profit: Rs 8.08 Cr; stable operational margins despite slight profit decline.

Geographical revenue split

Revenue primarily from Indian market; no detailed geos disclosed.

Order book

-

Whats driving growth

Expansion in premium Eurohead segment, increased domestic customer base, enhanced distribution and third-party manufacturing growth.

Our future plans

Focus on segmentation via innovative containers to tap underserved markets and optimize manufacturing and distribution.

Our green promise

Adherence to environmental safety and statutory regulations; focus on clean operations and resource preservation.

Our people and values

Employs around 194 staff emphasizing training, cordial industrial relations, and compliance with codes of conduct.

Key challenges ahead

Managing cost pressures, competitive market dynamics, and regulatory compliance.

Interesting facts

First in India to adopt Blow Fill Seal technology for plastic IV fluids; continuous expansion in specialized Eurohead products.

Risks and strategy

Mitigation via risk management policy, enhancing cost efficiency, diversifying product portfolio, and robust regulatory compliance.

Market Footprint

Top Clients

Top Clients

Hospitals, healthcare providers, and pharmaceutical companies; operates primarily B2B and third-party manufacturing for injectables.

Top Products

Top Products

Sterile IV fluids in glass and plastic bottles (100-1000 ml), Aquapulse Eurohead IV fluids, third-party manufacturing services.

Price Movement & Share Holding

Today's High/Low

60.3561.87

52 Week High/Low

56.194.6
Past Returns

1 week

0.47%

1 month

-10.71%

3 month

-12.43%

1 year

-31.68%

3 year

-38.17%

5 year

-7.71%

Share Holding

Promoters

38.98%

FII

0.01%

DII

0%

Retail

37.64%

Others

23.37%

Company Overview

Founded Year

1980

Listed Year

-

Headquarter

India

MD/CEO

Dr. Himanshu C. Patel (Managing Director) with leadership focus on expansion and modernization.

Website

http://www.denischemlab.com

Price Movement & Share Holding

Today's High/Low

60.3561.87

52 Week High/Low

56.194.6

Past Returns

1 week

0.47%

1 month

-10.71%

3 month

-12.43%

1 year

-31.68%

3 year

-38.17%

5 year

-7.71%

Share Holding

Promoters

38.98%

FII

0.01%

DII

0%

Retail

37.64%

Others

23.37%

Company Facts

What we do

Denis Chem Lab Ltd manufactures pharmaceutical transfusion solutions and intravenous fluids using advanced Blow Fill Seal technology, serving the healthcare sector with sterile injectable products.

Founded in

1980

Market share

A leading manufacturer in India's IV fluids segment with growing market presence in premium Eurohead products.

Problem solved

Provides safe, sterile intravenous fluids and transfusion solutions crucial for medical treatments and patient hydration.

Top clients or who we serve

Hospitals, healthcare providers, and pharmaceutical companies; operates primarily B2B and third-party manufacturing for injectables.

Key management

Dr. Himanshu C. Patel (Managing Director) with leadership focus on expansion and modernization.

Our journey and innovations

Started in 1984, innovated with BFS technology for plastic IV fluids in 2007, expanded Eurohead Aquapulse range in 2018 and 2021.

Where we operate

Primarily India domestic market with expanding geographical reach through enhanced distribution.

Top products or what we offer

Sterile IV fluids in glass and plastic bottles (100-1000 ml), Aquapulse Eurohead IV fluids, third-party manufacturing services.

Top brands

Aquapulse - premium Eurohead IV fluid brand with 12 lakh bottles/month capacity; key revenue driver.

Raw materials needed

Pharmaceutical grade chemicals and plastics for IV fluid production.

Raw materials supplier

Suppliers of medical-grade bulk drugs and plastics; specific names not disclosed.

Recurring vs cyclical contribution

Revenue largely recurring through steady IV fluid and transfusion solution demand.

Our industry position

Strong position in Indian sterile IV fluid segment with growing premium product line and third-party manufacturing.

Financial highlights

FY 2024-25 Revenue: Rs 173.3 Cr, Net Profit: Rs 8.08 Cr; stable operational margins despite slight profit decline.

Geographical revenue split

Revenue primarily from Indian market; no detailed geos disclosed.

Whats driving growth

Expansion in premium Eurohead segment, increased domestic customer base, enhanced distribution and third-party manufacturing growth.

Our future plans

Focus on segmentation via innovative containers to tap underserved markets and optimize manufacturing and distribution.

Our green promise

Adherence to environmental safety and statutory regulations; focus on clean operations and resource preservation.

Our people and values

Employs around 194 staff emphasizing training, cordial industrial relations, and compliance with codes of conduct.

Key challenges ahead

Managing cost pressures, competitive market dynamics, and regulatory compliance.

Interesting facts

First in India to adopt Blow Fill Seal technology for plastic IV fluids; continuous expansion in specialized Eurohead products.

Risks and strategy

Mitigation via risk management policy, enhancing cost efficiency, diversifying product portfolio, and robust regulatory compliance.

Market Footprint

Top Clients

Top Clients

Hospitals, healthcare providers, and pharmaceutical companies; operates primarily B2B and third-party manufacturing for injectables.

Top Products

Top Products

Sterile IV fluids in glass and plastic bottles (100-1000 ml), Aquapulse Eurohead IV fluids, third-party manufacturing services.

StockkASK provides smart, AI-powered insights to support analysis. AI can make mistakes; verify independently before investing.Terms & Conditions